India Pharma Outlook Team | Monday, 01 September 2025
Sai Life Sciences, a Contract Research, Development, and Manufacturing Organization (CRDMO) focused on innovation, has announced the successful completion of Phase II of its new Production Block (PB-11) at the company’s primary API manufacturing facility located in Bidar, India (Unit IV).
Phase I of PB-11, which has a capacity of 110 KL, was officially inaugurated in December 2024. With the addition of Phase II (~91 KL) in the first quarter of FY26, the total capacity of the block now reaches approximately 200 KL, establishing it as the largest reactor volume block at the Bidar site. This expansion has increased the company’s overall installed reactor capacity at the Bidar facility to around 700 KL.
Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said: “Our clients are at the heart of everything we do. This expansion at Bidar is more than additional capacity it is about giving our partners the confidence that we can scale with their needs, deliver reliably, and adapt to the increasing complexity of their programs.
By strengthening our large-scale API and intermediate manufacturing, we are enabling our clients to move faster, de-risk their supply chains, and bring new medicines to market with greater assurance.” PB-11 is a versatile production block engineered to accommodate large-scale commercial products.
Also Read: Lupin Secures US FDA Nod for Pithampur manufacturing facility
Sai Life Sciences’ Unit IV, located in Bidar, serves as the company’s premier manufacturing facility, focusing on the production of APIs and advanced intermediates for highly regulated markets, including the US, EU, and Japan.
